Carcinoma, Neuroendocrine: 436 Clinical Trials, Page 20 of 44

Hide Studies Not Open or Pending

194

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Condition(s):Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic CancerLast Updated:January 3, 2024Recruiting

195

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Condition(s):Stage III Breast Cancer; Stage IV Breast Cancer; Stage III Lung Cancer; Stage IV Lung Cancer; AML; Multiple Myeloma in Relapse; Carcinoma; Carcinoma, Pancreatic; Carcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma Breast; Carcinoma Prostate; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Lung; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Esophagus; Carcinoma Cervix; Carcinoma, Thymic; Carcinoma, Ductal; Carcinoma of the Head and Neck; Carcinoma of the Lip; Carcinoma of the Oral Cavity; Carcinoma of Unknown Primary; Carcinoma of the Skin; Carcinoma of the Anus; Carcinoma of the Larynx; Carcinoma of the Penis; Carcinoma of the Oropharynx; Carcinoma of the Appendix; Carcinoma of the Paranasal Sinus; Carcinoma of the Vulva; Malignant Pleural Effusion; Malignant Ascites; Mesothelioma; CholangiocarcinomaLast Updated:December 6, 2023Not yet recruiting

198

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Condition(s):Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8Last Updated:December 5, 2023Active, not recruiting

199

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Condition(s):RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal DiseaseLast Updated:February 22, 2024Active, not recruiting

200

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Condition(s):Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary CarcinomaLast Updated:June 13, 2016Completed

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.